19 July 2019 - - German drugmaker Boehringer Ingelheim and South Korea-based Bridge Biotherapeutics Inc. are entering into a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics's autotaxin inhibitor BBT-877 for patients with fibrosing interstitial lung diseases, including IPF, the companies said.
BBT-877 is currently in Phase I clinical studies and is anticipated to enter Phase II testing within the next 12 months.
Both companies will initially focus on developing the compound for the treatment of IPF, an area of high-unmet medical need and one of the key focus areas of Boehringer Ingelheim.
Boehringer Ingelheim has developed OFEV (nintedanib), an antifibrotic drug shown to slow disease progression by reducing lung function decline and currently approved for the treatment of IPF in more than 70 countries around the world including the US, the EU and Japan.
IPF is a rare, debilitating and fatal lung disease affecting approximately three m people worldwide. It causes progressive scarring of the lungs, resulting in continual and irreversible deterioration in lung function and breathing difficulties. BBT-877 inhibits autotaxin, an enzyme mediating a key pro-fibrotic event in multiple cell types.
It has shown a promising safety and efficacy profile in pre-clinical models for fibrosing interstitial lung diseases and potential for combination with the current standard of care.
Bridge Biotherapeutics will receive upfront and near term payments of EUR 45 m and is eligible to receive up to more than EUR 1.1bn in potential payments based upon the successful achievement of specified development, regulatory, and commercial milestones and staggered, up to double digit royalties.